These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
201 related articles for article (PubMed ID: 23741517)
1. Mapping the epitopes of a neutralizing antibody fragment directed against the lethal factor of Bacillus anthracis and cross-reacting with the homologous edema factor. Thullier P; Avril A; Mathieu J; Behrens CK; Pellequer JL; Pelat T PLoS One; 2013; 8(5):e65855. PubMed ID: 23741517 [TBL] [Abstract][Full Text] [Related]
2. High-affinity, human antibody-like antibody fragment (single-chain variable fragment) neutralizing the lethal factor (LF) of Bacillus anthracis by inhibiting protective antigen-LF complex formation. Pelat T; Hust M; Laffly E; Condemine F; Bottex C; Vidal D; Lefranc MP; Dübel S; Thullier P Antimicrob Agents Chemother; 2007 Aug; 51(8):2758-64. PubMed ID: 17517846 [TBL] [Abstract][Full Text] [Related]
4. The major neutralizing antibody responses to recombinant anthrax lethal and edema factors are directed to non-cross-reactive epitopes. Nguyen ML; Terzyan S; Ballard JD; James JA; Farris AD Infect Immun; 2009 Nov; 77(11):4714-23. PubMed ID: 19720758 [TBL] [Abstract][Full Text] [Related]
5. [Screening of full human anthrax lethal factor neutralizing antibody in transgenic mice]. Wang X; Chi X; Liu J; Liu W; Liu S; Qiu S; Wen Z; Fan P; Liu K; Song X; Fu L; Zhang J; Yu C Sheng Wu Gong Cheng Xue Bao; 2016 Nov; 32(11):1590-1599. PubMed ID: 29034628 [TBL] [Abstract][Full Text] [Related]
6. A Diverse Set of Single-domain Antibodies (VHHs) against the Anthrax Toxin Lethal and Edema Factors Provides a Basis for Construction of a Bispecific Agent That Protects against Anthrax Infection. Vrentas CE; Moayeri M; Keefer AB; Greaney AJ; Tremblay J; O'Mard D; Leppla SH; Shoemaker CB J Biol Chem; 2016 Oct; 291(41):21596-21606. PubMed ID: 27539858 [TBL] [Abstract][Full Text] [Related]
7. Toxin-neutralizing antibodies elicited by naturally acquired cutaneous anthrax are elevated following severe disease and appear to target conformational epitopes. Dumas EK; Demiraslan H; Ingram RJ; Sparks RM; Muns E; Zamora A; Larabee J; Garman L; Ballard JD; Boons GJ; James JA; Kayabas U; Doganay M; Farris AD PLoS One; 2020; 15(4):e0230782. PubMed ID: 32294093 [TBL] [Abstract][Full Text] [Related]
8. A novel mechanism for antibody-based anthrax toxin neutralization: inhibition of prepore-to-pore conversion. Mechaly A; Levy H; Epstein E; Rosenfeld R; Marcus H; Ben-Arie E; Shafferman A; Ordentlich A; Mazor O J Biol Chem; 2012 Sep; 287(39):32665-73. PubMed ID: 22869370 [TBL] [Abstract][Full Text] [Related]
9. Role of toxin functional domains in anthrax pathogenesis. Brossier F; Weber-Levy M; Mock M; Sirard JC Infect Immun; 2000 Apr; 68(4):1781-6. PubMed ID: 10722564 [TBL] [Abstract][Full Text] [Related]
10. Neutralizing activity of vaccine-induced antibodies to two Bacillus anthracis toxin components, lethal factor and edema factor. Taft SC; Weiss AA Clin Vaccine Immunol; 2008 Jan; 15(1):71-5. PubMed ID: 18032590 [TBL] [Abstract][Full Text] [Related]
12. Development of a novel multiepitope chimeric vaccine against anthrax. Aggarwal S; Somani VK; Gupta S; Garg R; Bhatnagar R Med Microbiol Immunol; 2019 Apr; 208(2):185-195. PubMed ID: 30671633 [TBL] [Abstract][Full Text] [Related]
13. Adenoviral Expression of a Bispecific VHH-Based Neutralizing Agent That Targets Protective Antigen Provides Prophylactic Protection from Anthrax in Mice. Moayeri M; Tremblay JM; Debatis M; Dmitriev IP; Kashentseva EA; Yeh AJ; Cheung GY; Curiel DT; Leppla S; Shoemaker CB Clin Vaccine Immunol; 2016 Jan; 23(3):213-8. PubMed ID: 26740390 [TBL] [Abstract][Full Text] [Related]
14. The early humoral immune response to Bacillus anthracis toxins in patients infected with cutaneous anthrax. Brenneman KE; Doganay M; Akmal A; Goldman S; Galloway DR; Mateczun AJ; Cross AS; Baillie LW FEMS Immunol Med Microbiol; 2011 Jul; 62(2):164-72. PubMed ID: 21401726 [TBL] [Abstract][Full Text] [Related]
15. Identification and characterization of immunodominant B-cell epitope of the C-terminus of protective antigen of Bacillus anthracis. Kaur M; Chug H; Singh H; Chandra S; Mishra M; Sharma M; Bhatnagar R Mol Immunol; 2009 Jun; 46(10):2107-15. PubMed ID: 19356802 [TBL] [Abstract][Full Text] [Related]
16. Neutralizing monoclonal antibodies directed against defined linear epitopes on domain 4 of anthrax protective antigen. Kelly-Cirino CD; Mantis NJ Infect Immun; 2009 Nov; 77(11):4859-67. PubMed ID: 19703971 [TBL] [Abstract][Full Text] [Related]
18. The 2beta2-2beta3 loop of anthrax protective antigen contains a dominant neutralizing epitope. Zhang J; Xu J; Li G; Dong D; Song X; Guo Q; Zhao J; Fu L; Chen W Biochem Biophys Res Commun; 2006 Mar; 341(4):1164-71. PubMed ID: 16460675 [TBL] [Abstract][Full Text] [Related]
19. Lethal factor antibodies contribute to lethal toxin neutralization in recipients of anthrax vaccine precipitated. Dumas EK; Garman L; Cuthbertson H; Charlton S; Hallis B; Engler RJM; Choudhari S; Picking WD; James JA; Farris AD Vaccine; 2017 Jun; 35(26):3416-3422. PubMed ID: 28504191 [TBL] [Abstract][Full Text] [Related]
20. Epitope mapping of the protective antigen of B. anthracis by using nanoclusters presenting conformational peptide epitopes. Gerdon AE; Wright DW; Cliffel DE Angew Chem Int Ed Engl; 2006 Jan; 45(4):594-8. PubMed ID: 16355420 [No Abstract] [Full Text] [Related] [Next] [New Search]